TALS - Talaris Therapeutics, Inc. Stock Price, Fair Value and News

$2.72-0.02 (-0.73%)

Market Closed as of 19 Oct 2023, 04:00 pm ET

TALS Stock Valuation Analysis

Valuation

Max Portfolio %

TALS Price Action

TALS RSI Chart

TALS Stock Valuation Analysis

Valuation

Max Portfolio %

TALS Valuation

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

TALS Fundamentals

TALS Revenue

TALS Earnings

TALS Profitability

TALS Investor Care

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

Net sales

Year	Q1	Q2	Q3	Q4
2023	-	-	-	-
2022	-	-	-	-

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Talaris Therapeutics, Inc.

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts.

CEO	Ms. Mary Kay Fenton
WEBSITE	https://talaristx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	84